A5048676751- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Lung Cancer Treatments and Mutations
- Neuroblastoma Research and Treatments
- Lung Cancer Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Metastasis and carcinoma case studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Pancreatic and Hepatic Oncology Research
- Occupational and environmental lung diseases
- Gastric Cancer Management and Outcomes
- Sarcoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- RNA modifications and cancer
- Cancer Cells and Metastasis
- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- Tracheal and airway disorders
- Cancer-related Molecular Pathways
- Protein Degradation and Inhibitors
- Myasthenia Gravis and Thymoma
University of Milan
2015-2024
University of Florence
2000-2024
MultiMedica
2017-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2014-2024
University of Turin
2023
Casa Sollievo della Sofferenza
2023
ORCID
2023
Institute for Stem Cell Biology and Regenerative Medicine
2023
Fondazione IRCCS Istituto Nazionale dei Tumori
2010-2019
Luigi Sacco Hospital
2013-2019
Analysis of circulating DNA in plasma can provide a useful marker for earlier lung cancer detection. This study was designed to assess the sensitivity and specificity quantitative molecular assay identify patients with monitor their disease.The amount determined through use real-time polymerase chain reaction (PCR) amplification human telomerase reverse transcriptase gene (hTERT) 100 non-small-cell age-, sex-, smoking-matched controls. Screening performance calculated receiver operating...
Notch signaling regulates cell specification and homeostasis of stem compartments, it is counteracted by the fate determinant Numb. Both Numb have been implicated in human tumors. Here, we show that altered approximately one third non–small-cell lung carcinomas (NSCLCs), which are leading cause cancer-related deaths: ≈30% NSCLCs, loss expression leads to increased activity, while a smaller fraction cases (around 10%), gain-of-function mutations NOTCH-1 gene present. Activation correlates...
The antineoplastic, prodifferentiative effects of bromodomain and extra-terminal (BET) (BRD) inhibitors were initially discovered in NUT midline carcinoma (NMC), an aggressive subtype squamous cancer driven by the BRD4-NUT fusion oncoprotein. blocks differentiation maintains tumor growth through a potent chromatin-modifying mechanism. OTX015/MK-8628, novel oral BET inhibitor, targets BRD2/3/4/T with preclinical activity NMC several other types is currently clinical development. Antitumor was...
Lung cancer is the first cause of mortality worldwide, and its early detection currently main available strategy to improve disease prognosis. While diagnosis can be successfully achieved through tomography-based population screenings in high-risk individuals, simple methodologies are needed for effective prevention programs. We developed a test, based on 34 microRNAs (miRNAs) from serum, that could identify patients with stage non-small cell lung carcinomas (NSCLCs) asymptomatic individuals...
Lung neuroendocrine tumors are catalogued in four categories by the World Health Organization (WHO 2004) classification. Its reproducibility and prognostic efficacy was disputed. The WHO 2010 classification of digestive neoplasms is based on Ki67 proliferation assessment proved prognostically effective. This study aims at comparing these two classifications defining a grading system for lung tumors. included 399 patients who underwent surgery with least 1 year follow-up between 1989 2011....
Next-generation sequencing (NGS) was applied to 148 lung neuroendocrine tumours (LNETs) comprising the four World Health Organization classification categories: 53 typical carcinoid (TCs), 35 atypical (ACs), 27 large-cell carcinomas, and 33 small-cell carcinomas. A discovery screen conducted on 46 samples by use of whole-exome high-coverage targeted 418 genes. Eighty-eight recurrently mutated genes from both current literature were verified in cases screen, validated additional 102 LNETs...
Abstract The worldwide incidence of pulmonary carcinoids is increasing, but little known about their molecular characteristics. Through machine learning and multi-omics factor analysis, we compare contrast the genomic profiles 116 (including 35 atypical), 75 large-cell neuroendocrine carcinomas (LCNEC), 66 small-cell lung cancers. Here report that integrative analyses on 257 neoplasms stratify atypical into two prognostic groups with a 10-year overall survival 88% 27%, respectively. We...
Seven patients with typical or atypical pulmonary carcinoid tumors overdiagnosed as small-cell carcinoma on bronchoscopic biopsies are described. Bronchial from 9 consecutive lung were used control group for histologic and immunohistochemical studies (cytokeratins, chromogranin A, synaptophysin, Ki-67 [MIB-1], TTF-1). The presented either central peripheral lesions composed of tumor cells granular, sometimes coarse chromatin pattern, high levels A/synaptophysin immunoreactivity, low (<20%)...
Background: Tamoxifen reduces the risk of breast cancer in women at high for disease but increases endometrial tumors and venous thromboembolisms, possibly a dose-dependent fashion. We compared effects tamoxifen 1 mg/day 5 with those standard dose 20 on proliferation using surrogate endpoint marker (Ki-67 expression) blood biomarkers associated cancer, cardiovascular disease, bone fracture risk. Methods: randomly assigned 120 estrogen receptor (ER)-positive to 1, 5, or 4 weeks. Expression...
Abstract Purpose: Both therapeutic and adverse effects of tamoxifen may be related to its tissue concentrations. We investigated concentrations tamoxifen, 4-hydroxytamoxifen, N-desmethyltamoxifen, N-didesmethyltamoxifen in serum, normal breast, breast cancer tissues during conventional dosage two low-dose regimens. Furthermore we studied on the proliferation marker Ki-67, sex hormone-binding globulin (SHBG). Experimental Design: From September 1999 August 2001, 120 patients were randomized...